Estradiol valerate is a synthetic prodrug that converts into estradiol, the primary estrogen hormone naturally produced in the human body. It’s used to treat menopausal symptoms, low estrogen conditions, and as part of gender-affirming hormone therapy. Once absorbed, the body cleaves off the valerate ester, releasing the same 17β-estradiol your ovaries would produce, making it bioidentical in its final form.
How Estradiol Valerate Works
The “valerate” part of the name refers to a fatty acid chain attached to the estradiol molecule. This chemical modification makes the compound more fat-soluble, which serves two practical purposes: it improves oral absorption when taken as a pill, and it creates a slow-release depot when injected into muscle tissue. After you take it, enzymes in the liver strip away the valerate chain, leaving behind plain estradiol that circulates through your bloodstream and binds to estrogen receptors throughout the body.
This is the same mechanism used by other estradiol esters like estradiol cypionate and estradiol benzoate. The difference between them comes down to the length of the fatty acid chain. Cypionate has 8 carbons in its chain compared to valerate’s 5, which makes cypionate more fat-soluble and slower to release. That’s why the two esters produce different blood level patterns even though they deliver the same hormone.
What It’s Prescribed For
Estradiol valerate has three main FDA-approved uses: treating moderate to severe hot flashes and night sweats during menopause, relieving vaginal dryness and tissue thinning associated with menopause, and replacing estrogen in people whose bodies don’t produce enough due to conditions like primary ovarian failure or surgical removal of the ovaries.
Beyond these approved uses, estradiol valerate is one of the most commonly prescribed estrogens in feminizing gender-affirming hormone therapy. In this context, oral doses typically start at 2 to 4 mg daily and can be increased up to 8 mg, depending on blood levels and clinical response. Injectable forms are also widely used, with dosing adjusted based on individual monitoring.
Available Forms and How They Differ
Estradiol valerate comes in oral tablets and injectable oil solutions. The route you use significantly affects how much estrogen reaches your bloodstream and how stable your levels stay between doses.
Intramuscular injections generally produce higher peak estradiol levels than oral or transdermal routes. With a typical 4 to 5 mg injection of estradiol valerate, blood levels peak around day 2 at roughly 400 to 667 pg/mL, then gradually decline over about 14 days. This creates a wave pattern: levels spike after injection, then drop before the next dose. Some people notice mood or energy shifts that follow this cycle.
Oral tablets avoid the peaks and troughs of injections but pass through the liver first (called first-pass metabolism), which means a larger proportion of the hormone is processed before it can circulate. This liver processing is also what contributes to a slightly higher clotting risk with oral estrogen compared to forms that bypass the liver.
Subcutaneous injection (into the fat layer under the skin rather than into muscle) is sometimes used as well, though research suggests it may produce lower estradiol levels than intramuscular injection. One study found mean estradiol levels of 294 pg/mL with intramuscular injection versus 131 pg/mL with subcutaneous injection at six months, even after adjusting for dose and body weight.
Estradiol Valerate vs. Estradiol Cypionate
These are the two injectable estradiol esters you’ll encounter most often, and they’re not interchangeable on a one-to-one basis. A pharmacokinetic comparison found that estradiol valerate peaks faster, around day 2 after injection, while cypionate takes about 4 days to reach its peak. Valerate also produces higher peak blood levels but doesn’t last as long: elevated estrogen levels persist for 7 to 8 days with valerate versus about 11 days with cypionate.
In practical terms, this means valerate is usually injected more frequently (every 5 to 7 days for many patients) while cypionate can be spaced further apart (every 7 to 14 days). Valerate’s faster peak and shorter duration actually led researchers to describe it as having “the most predictable pharmacokinetics” of the estradiol esters. That predictability can make dose adjustments more straightforward.
Risks and Side Effects
The most serious risk associated with estrogen therapy, including estradiol valerate, is blood clots. Venous thromboembolism (clots in the deep veins of the legs or lungs) is the most common serious complication, and it tends to occur within the first few months of starting treatment. The risk is real but relatively small in absolute terms.
Route of administration matters here. A meta-analysis of 15 observational studies found that oral estrogen therapy carried a 63% higher risk of a first blood clot episode and roughly double the risk of deep vein thrombosis compared to transdermal (patch) estrogen in postmenopausal women. This is because oral estrogen passes through the liver and activates clotting factors more than forms absorbed through the skin or muscle. For people with additional clot risk factors like obesity, smoking, or a personal or family history of blood clots, non-oral routes are generally preferred.
More common, less serious side effects include breast tenderness, headaches, nausea (especially with oral forms), bloating, and mood changes. Many of these improve after the first few months as the body adjusts.
Who Should Avoid It
Estradiol valerate is not appropriate for people with a history of estrogen-dependent cancers (such as certain breast cancers), active blood clots or a history of clotting disorders, undiagnosed abnormal uterine bleeding, or liver disease. Pregnancy is an absolute contraindication. People with a history of stroke or heart attack should discuss the risks carefully with their provider, as estrogen can affect cardiovascular health depending on timing, dose, and delivery method.
Storing Injectable Estradiol Valerate
Injectable estradiol valerate is suspended in oil (typically castor oil or sesame oil) and should be stored at room temperature. If the solution looks cloudy or contains visible particles, it should not be used. Cold temperatures can cause the oil to thicken or crystallize, so avoid refrigerating it. If the vial has been exposed to cold and the solution looks unusual, warming it gently between your hands can help, but persistent cloudiness means the vial should be discarded.